Quintiles completes assets sale

Published: 12-Aug-2004

Quintiles Transnational has completed the sale of assets relating to its specialty dermatology products company, Bioglan Pharmaceuticals, to BDY Acquisition, a Delaware corporation and wholly owned subsidiary of Bradley Pharmaceuticals for $188.3m in cash, including approximately $5.4m of direct costs for transferred inventory.


Quintiles Transnational has completed the sale of assets relating to its specialty dermatology products company, Bioglan Pharmaceuticals, to BDY Acquisition, a Delaware corporation and wholly owned subsidiary of Bradley Pharmaceuticals for $188.3m in cash, including approximately $5.4m of direct costs for transferred inventory.

Quintiles intends to use proceeds from the transaction to potentially pay down debt, to fund business growth initiatives and for other appropriate purposes.

The assets sold to Bradley's subsidiary include Bioglan's interests in certain dermatology products marketed in the US, including Solaraze (diclofenac sodium) Gel, a topical treatment for the pre-cancerous skin condition actinic keratosis; the prescription product Adoxa (doxycycline) for the oral treatment of severe acne; Zonalon (doxepin hydrochloride), a topical treatment indicated for pruritus; and Tx Systems, a line of advanced topical treatments used during in-office procedures.

  • Companies:
  • IQVIA
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part II

Read more
In the second part of this article, the authors delve deeper into how effective change management enables pharmaceutical manufacturers to handle the challenges and risks of rapid, simultaneous industry shifts, thereby ensuring that quality and patient safety remain uncompromised throughout the process

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part II

In the second part of this article, the authors delve deeper into how effective change management enables pharmaceutical manufacturers to handle the challenges and risks of rapid, simultaneous industry shifts, thereby ensuring that quality and patient safety remain uncompromised throughout the process
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Drug Delivery

IQVIA discusses supply chain resilience for CPhI Discover

Informa’s CPhI Discover virtual event is taking place from 17-28th May, and the company recently spoke with Aurelio Arias, Engagement Manager, Thought Leadership at IQVIA ahead of a session he is moderating on the ‘API Landscape, Reshoring and sourcing dynamics’. (Thursday 20th at 3pm CET)

Quintiles outsource Verona COPD and cystic fibrosis therapeutics

Verona Pharma enters global strategic clinical development services agreement with QuintilesIMS for RPL554
Manufacturing

Quintiles to acquire Novella Clinical

To boost its small biopharma, oncology and medical device capabilities
Regulatory

Merck and Quintiles sign innovative clinical development partnership

Unique strategic collaboration for development and clinical trial execution
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Mega deals and job cuts

Mergers and acquisitions, job cuts as companies streamlined their operations and cut costs, and investments in new plants were the main features of the pharmaceutical industry in 2012
Subscribe now